PDF herunterladen
Aktuelle Neurologie 2005; 32(10): 609-622
DOI: 10.1055/s-2005-867035
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Drogen und Nervensystem (Teil 3): Differenzialdiagnose drogenassoziierter Zustände und kurzer Ausblick

Drugs and Nervous System (Part 3): Differential Diagnosis of Drug Associated States and Short ReflectionS.  Rüegg1
  • 1Abteilung für Klinische Neurophysiologie, Neurologische Klinik, Universitätsspital Basel, Schweiz
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
24. November 2005 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Weiterbildungsziele In diesem Beitrag sollen folgende Weiterbildungsziele vermittelt werden: Kenntnis der wichtigsten Intoxikations- und Entzugssymptome drogenassoziierter Zustände Kenntnis der wichtigsten Differenzialdiagnosen drogenassoziierter Zustände Kenntnis der Probleme der Polytoxikomanie Kenntnis der Gefahren und Problematik von so genannten „Designer Drugs” für den Konsumenten und den Arzt Kenntnis der medikamentösen therapeutischen Zukunftsperspektiven von Drogenabhängigkeit

Nachdem in den beiden vorangehenden Teilen dieser Übersichtsarbeit die Grundlagen der Drogenwirkung und Abhängigkeitsentwicklung sowie die einzelnen Drogen detailliert dargestellt worden sind, soll im nachfolgenden letzten Teil knapp und synoptisch die Differenzialdiagnose drogenassoziierter Zustände erläutert und ein kurzer Ausblick hinsichtlich zukünftiger Herausforderungen durch neue Drogen sowie therapeutischer Strategien getätigt werden.

Die klinisch-neurologische Differenzialdiagnose von drogeninduzierten Symptomen ist extrem breit (s. a. Tab. [1]).

Literatur

  • 1 Neiman J, Haapaniemi H M, Hilborn M. Neurological complications of drug abuse: pathophysiological mechanisms.  Eur J Neurol. 2000;  7 595-606
    CrossrefPubMedGoogle Scholar
  • 2 Hill M D, Cooper P W, Perry J R. Chasing the dragon - neurological toxicity associated with inhalation of heroin vapour: case report.  CMAJ. 2000;  162 236-238
    PubMedGoogle Scholar
  • 3 Long H, Deore K, Hoffman R S, Nelson L S. A fatal case of spongiform leukoencephalopathy linked to „chasing the dragon”.  J Toxicol Clin Toxicol. 2003;  41 887-891
    CrossrefPubMedGoogle Scholar
  • 4 Filley C M, Kleinschmidt-DeMasters B K. Toxic leukoencephalopathy.  New Engl J Med. 2001;  345 425-432
    CrossrefPubMedGoogle Scholar
  • 5 Alldredge B K, Lowenstein D H, Simon R P. Seizures associated with recreational drug abuse.  Neurology. 1989;  39 1037-1039
    PubMedGoogle Scholar
  • 6 Zagoni P G, Albano C. Psychostimulants and epilepsy.  Epilepsia. 2002;  43 (Suppl 2) S28-S31
    CrossrefPubMedGoogle Scholar
  • 7 Ben-Abraham R, Szold O, Rudick V, Weinbroum A A. „Ecstasy” intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting.  Eur J Emerg Med. 2003;  10 309-313
    PubMedGoogle Scholar
  • 8 Miro O, Nogue S, Espinosa G. et al . Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate.  J Toxicol Clin Toxicol. 2002;  40 129-135
    CrossrefPubMedGoogle Scholar
  • 9 Dyer J E. γ-Hydroxybutyrate: a health-food product producing coma and seizure-like activity.  Am J Emerg Med. 1991;  9 321-324
    CrossrefPubMedGoogle Scholar
  • 10 Lowenstein D H, Massa S M, Rowbotham M C. et al . Acute neurologic and psychiatric complications associated with cocaine abuse.  Am J Med. 1987;  83 841-846
    CrossrefPubMedGoogle Scholar
  • 11 Andersen S N, Skullerud K. Hypoxic/brain ischemia damage, especially pallidal lesions, in heroin addicts.  Forensic Sci Int. 1999;  102 51-59
    CrossrefPubMedGoogle Scholar
  • 12 Fessler R D, Esshaki C M, Stankewitz R C. et al . The neurovascular complications of cocaine.  Surg Neurol. 1997;  47 339-345
    CrossrefPubMedGoogle Scholar
  • 13 Aggarwal S K, Williams V, Levine S R. et al . Cocaine-associated intracranial hemorrhage: absence of vasculitis in 14 cases.  Neurology. 1996;  46 1741-1743
    PubMedGoogle Scholar
  • 14 Buxton N, McConachie N S. Amphetamine abuse and intracranial haemorrhage.  J R Soc Med. 2000;  93 472-477
    PubMedGoogle Scholar
  • 15 Perez Jr J A, Arsura E L, Strategos S. Methamphetamine-related stroke: four cases.  J Emerg Med. 1999;  17 469-471
    CrossrefPubMedGoogle Scholar
  • 16 McEvoy A W, Kitchen N D, Thomas D G. Intracerebral haemorrhage and drug abuse in young adults.  Br J Neurosurg. 2000;  14 449-454
    CrossrefPubMedGoogle Scholar
  • 17 Moussouttas M. Cannabis use and cerebrovascular disease.  Neurologist. 2004;  10 47-53
    CrossrefPubMedGoogle Scholar
  • 18 Dhuna A, Pascual-Leone A, Belgrade M. Cocaine-related vascular headaches.  J Neurol Neurosurg Psychiatry. 1991;  54 803-806
    PubMedGoogle Scholar
  • 19 Toth C. Medications and substances as a cause of headache: a systematic review of the literature.  Clin Neuropharmacol. 2003;  26 122-136
    PubMedGoogle Scholar
  • 20 Poole R, Brabbing C. Drug-induced psychosis.  Br J Psychiatry. 1996;  168 135-138
    PubMedGoogle Scholar
  • 21 Lejoyeux M, Mourad I, Ades J. Psychiatric disorders induced by drug dependence other than alcohol.  Encephale. 2000;  26 21-27
    PubMedGoogle Scholar
  • 22 Rogers R D, Robbins T W. Investigating the neurocognitive deficits associated with chronic drug misuse.  Curr Opin Neurobiol. 2001;  11 250-257
    CrossrefPubMedGoogle Scholar
  • 23 Nordahl T E, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review.  J Neuropsychiatry Clin Neurosci. 2003;  15 317-325
    PubMedGoogle Scholar
  • 24 Halpern J H, Pope Jr H G. Hallucinogen persisting perception disorder: what do we know after 50 years?.  Drug Alcohol Depend. 2003;  69 109-119
    CrossrefPubMedGoogle Scholar
  • 25 Halpern J H, Pope Jr H G, Sherwood A R. et al . Residual neuropsychological effects of illicit 3,4-methylendioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs.  Drug Alcohol Depend. 2004;  75 135-147
    PubMedGoogle Scholar
  • 26 McCardle K, Luebbers S, Carter J D. et al . Chronic MDMA (ecstasy) use, cognition and mood.  Psychopharmacology. 2004;  173 434-439
    CrossrefPubMedGoogle Scholar
  • 27 Vecellio M, Schopper C, Modestin J. Neuropsychiatric consequences (atypical psychosis and complex-partial seizures) of ecstasy use: possibile evidence for toxicity-vulnerability predictors and implications for preventive and clinical care.  J Psychopharmacol. 2003;  17 342-345
    CrossrefPubMedGoogle Scholar
  • 28 Henquet C, Krabbendam L, Spauwen J. et al . Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people.  BMJ. 2005;  330 11 , doi: 10.1136/bmj.38267.664086.63 (published 1 December 2004)
    CrossrefPubMedGoogle Scholar
  • 29 Manfredi P L, Gonzales G R, Payne R. Reversible spastic paraparesis induced by high-dose intravenous metadone.  J Pain. 2001;  2 77-79
    CrossrefPubMedGoogle Scholar
  • 30 Stamboulis E, Psimaras A, Malliara-loulakaki S. Brachial and lumbar plexitis as a reaction to heroin.  Drug Alcohol Depend. 1988;  22 205-207
    PubMedGoogle Scholar
  • 31 Bernasconi A, Kuntzer T, Ladbon N. et al . Complications neurologiques périphériques et médullaires de la toxicomanie intraveineuse à l'héroine.  Rev Neurol. 1996;  152 688-694
    PubMedGoogle Scholar
  • 32 Pestaner J P, Southall P E. Sudden death during arrest and phencyclidine intoxication.  Am J Forensic Med Pathol. 2003;  24 119-122
    CrossrefPubMedGoogle Scholar
  • 33 Green A R, O'Shea E, Colado M I. A review or the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response.  Eur J Pharmacol. 2004;  500 3-13
    CrossrefPubMedGoogle Scholar
  • 34 Holmes S B, Banerjee A K, Alexander W D. Hyponatraemia and seizures after ecstasy use.  Postgrad Med J. 1999;  75 32-34
    PubMedGoogle Scholar
  • 35 Hartung T K, Schofield E, Short A I. et al . Hyponatraemic states following 3,4-methylendioxymethamphetamine (MDMA, „Ecstasy”) ingestion.  Q J Med. 2002;  95 431-437
    PubMedGoogle Scholar
  • 36 Nath A, Maragos W F, Avison M J. et al . Acceleration of HIV dementia with methamphetamine and cocaine.  J Neurovirol. 2001;  7 66-71
    PubMedGoogle Scholar
  • 37 Friedman H, Eisenstein T K. Neurological basis of drug dependence and its effects on the immune system.  J Neuroimmunol. 2004;  147 106-108
    CrossrefPubMedGoogle Scholar
  • 38 Vallejo R, Leon-Casasola O de, Ramsun B. Opioid therapy and immunosuppression: a review.  Am J Ther. 2004;  11 354-365
    PubMedGoogle Scholar
  • 39 Connor T J. Methylendioxymethamphetamine (MDMA, „Ecstasy”): a stressor on the immune system.  Immunology. 2004;  111 357-367
    CrossrefPubMedGoogle Scholar
  • 40 Bialer P A. Designer drugs in the general hospital.  Psychiatr Clin North Am. 2002;  25 231-243
    CrossrefPubMedGoogle Scholar
  • 41 Staack R F, Maurer H H. Metabolism of designer drugs of abuse.  Curr Drug Metab. 2005;  6 259-274
    CrossrefPubMedGoogle Scholar
  • 42 Sassenbroeck D K Van, Calle P A, Rousseau F M. et al . Medical problems related to recreational drug use at nocturnal dance parties.  Eur J Emerg Med. 2003;  10 302-308
    PubMedGoogle Scholar
  • 43 Refstad S. Paramethoxyamphetamine (PMA) poisoning: a „party drug” with lethal effect.  Acta Anaesthesiol Scand. 2003;  47 1298-1299
    CrossrefPubMedGoogle Scholar
  • 44 Becker J, Neis P, Röhrich J, Zörntlein S. A fatal Paroxymethamphetamin intoxication.  Legal Med. 2003;  5 (Suppl) S138-S141
    PubMedGoogle Scholar
  • 45 Amato L, Davoli M, Minozzi S. et al .Metadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2005 Jul 20 (3) CD003409
    Google Scholar
  • 46 Ferri M, Davoli M, Amato L. Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev 2005 Apr 18 (2) CD003410
    Google Scholar
  • 47 Amato L, Davoli M, Perucci C A. et al . An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research.  J Subst Abuse Treat. 2005;  28 321-329
    CrossrefPubMedGoogle Scholar
  • 48 Kosten T R, O'Connor P G. Management of drug and alcohol withdrawal.  New Engl J Med. 2003;  348 1786-1795
    CrossrefPubMedGoogle Scholar
  • 49 Umbricht A, Hoover D R, Tucker M J. et al . Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.  Drug Alcohol Depend. 2003;  69 263-272
    CrossrefPubMedGoogle Scholar
  • 50 Bochud Tornay C, Favrat B, Monnat M. et al . Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine preparation: long-term results.  Drug Alcohol Depend. 2003;  69 283-288
    PubMedGoogle Scholar
  • 51 Digiusto E, Lintzeris N, Breen C. et al for the NEPOD Research Group . Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project.  Addict Behav. 2005;  30 443-456
    CrossrefPubMedGoogle Scholar
  • 52 Richmond R, Zwar N. Review of bupropion for smoking cessation.  Drug Alcohol Rev. 2003;  22 203-222
    PubMedGoogle Scholar
  • 53 Aubin H J, Lebargy F, Berlin I. et al . Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.  Addiction. 2004;  99 1206-1218
    CrossrefPubMedGoogle Scholar
  • 54 Fernandez J R, Allison D B. Rimonabant Sanofi-Synthélabo.  Curr Opin Invest Drugs. 2004;  5 430-435
    PubMedGoogle Scholar
  • 55 Boyd S T, Fremming B A. Rimonabant - a selective CB1 antagonist.  Ann Pharmacother. 2005;  39 684-690
    PubMedGoogle Scholar
  • 56 Gaal L F Van, Rissanen A M, Scheen A J. et al . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.  Lancet. 2005;  365 1389-1397
    CrossrefPubMedGoogle Scholar
  • 57 Kantak K M. Vaccines against drugs of abuse: a viable treatment option?.  Drugs. 2003;  63 341-352
    PubMedGoogle Scholar
  • 58 Martell B A, Mitchell E, Poling J. et al . Vaccine pharmacotherapy for the treatment of cocaine dependence.  Biol Psychiatry. 2005;  58 158-164
    CrossrefPubMedGoogle Scholar
  • 59 Ashcroft R E, Franey C. Further ethical and social issues in using a cocaine vaccine: response to Hall and Carter.  J Med Ethics. 2004;  30 341-343
    CrossrefPubMedGoogle Scholar

Dr. med. Stephan Rüegg

Abt. f. klinische Neurophysiologie · Neurologische Klinik · Universitätsspital

Petersgraben 4

4031 Basel · Schweiz

eMail: srueegg@uhbs.ch

      >